Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact

Author's Take

In this video collection, authors of findings published in JCI Insight present personally guided tours of their results. The journal accepts video submissions from authors of recently accepted manuscripts. Instructions can be found on the Author's Take Guidelines page.

Clinical trial evaluates R. mucosa for atopic dermatitis

The inflammatory skin disease atopic dermatitis is characterized by decreased epidermal barrier function, susceptibility to S. aureus infection, and immune dysfunction. Recently, the commensal bacterium Roseomonas mucosa was shown to improve atopic dermatitis-like phenotypes in murine models.  In this episode, Ian Myles and colleagues evaluate safety and efficacy of topical administration of R. mucosa in a small cohort of adults and children with atopic dermatitis. Overall, R. mucosa treatment was considered safe and reduced disease severity in both children and adults. The results from this initial study supports further evaluation of topical R. mucosa for treating atopic dermatitis.


Infancy gene signature helps predict type 1 diabetes progression

Type 1 diabetes (T1D) results from autoimmune-mediated destruction of insulin-producing pancreatic β cells. While there is a genetic component to T1D, there is no reliable way to identify which genetically at-risk individuals will develop autoantibodies. In this episode, Mark Harris, Ahmed Mehdi, and Ranjeny Thomas discuss their work, which identifies a gene expression signature during infancy that when combined with HLA risk score predicts later seroconversion in genetically at-risk subjects. Use of this signature has potential to improve early diagnosis and treatment intervention for those at risk of developing T1D.


Identification of eosinophilic esophagitis-associated genes

Eosinophilic esophagitis (EoE) is a chronic allergic disorder that presents with difficulty swallowing, vomiting, failure to thrive, and food impaction in adulthood. Several EoE-associated pathways have been identified; however, the underlying genetic causes of this disorder are poorly understood. In this episode, Marc Rothenberg and colleagues used whole-exome sequencing and identified EoE-associated variants in the mitochondrial oxioreductases DHTKD1 and OGDHL. In T cells, loss of DHTKD1 function increased ROS and viperin, which promotes Th2 cytokine production. Moreover, viperin was increased in esophageal biopsies from EoE patients. Together, these results implicate mitochondrial dysfunction in EoE pathogenesis.


Identifying a role for osteopontin in Alport syndrome

Alport syndrome is a rare hereditary renal disease that is characterized by blood and protein in the urine, hypertension, progressive kidney failure, hearing loss, and eye abnormalities. While it is possible to diagnose the disease early, current therapies are unable to prevent end-stage kidney failure. In this episode, Lina Shehadeh and colleagues determined that osteopontin is highly upregulated in the renal tubules of a mouse model of Alport syndrome and promotes excessive cholesterol influx to the kidney. Deletion of the osteopontin-encoding gene ameliorated Alport-associated disease manifestations and improved lifespan. Together, these results identify osteopontin as a driver of renal dysfunction in Alprot syndrome and provides potential therapeutic targets to be further explored.

 


Role for GARP-TGF-β on B cells in immune tolerance

The transmembrane protein GARP serves as a receptor for latent TGF-β, resulting in activation of this cytokine. GARP is expressed on the surface of Tregs, tumors, and platelets and has been implicated in cancer immune invasion. In this episode, Zihai Li and colleagues reveal that the GARP-TGF-β complex is present on activated, but not resting, human and murine B cells. Using multiple murine genetic models, the authors determined that this complex is essential for maintaining immune tolerance and for preventing autoimmune disease. These results support further exploration of B cell GARP as a therapeutic target and possible diagnostic tool.

  • ← Previous
  • 1
  • 2
  • …
  • 13
  • 14
  • 15
  • Next →
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts